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Abstract
Background: Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory childhood myopathy of uncertain
aetiology. The demographic and clinical presentation of JDM may differ by race and geographic regions.
Few studies have described the characteristics of JDM patients from Africa.
Methods: We conducted a retrospective observational study to determine clinical characteristics and outcomes of
patients satisfying the Bohan and Peter criteria for probable JDM seen between 2004 and 2013 in three hospitals in
Cape Town, South Africa.
Results: Twenty five cases were identified: 16 female and 9 male; thirteen (52 %) were of indigenous African,
eleven (44 %) mixed and one (4 %) European ancestry. The median ages at disease onset and diagnosis were
6.75 (range 2.0–9.7) and 7.9 (range 3.4–9.75) years respectively. Eleven patients had calcinosis while the mortality was 2/
25 (8 %). Only 40 % of the patients had clinically inactive disease by PRINTO criteria (modified) at last review. There was
no statistically significant difference in racial distribution (p-value = 1), age at disease onset (p-value = 0.87) and disease
duration prior to treatment initiation (p-value = 0.75) between patients who had clinically active and inactive disease.
Conclusion: The demographic characteristics of children with JDM were similar to that from most other regions of the
world with female predominance and similar age at onset. Majority of the patients remained with clinically active
disease, which put them at risk of further disease complications. Long term follow up and use of appropriate
treatment guidelines may be indicated in management of JDM patients for optimum treatment outcomes.
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Background
Juvenile dermatomyositis (JDM) is an immune mediated
vasculopathic disease of childhood characterized by
inflammation of the striated muscles, skin and internal
organs. The most common clinical manifestations are
proximal muscle weakness and characteristic cutaneous
lesions such as heliotrope rash, Gottron’s papules and
calcinosis. However, disease manifestations may occur in
the lungs, heart, gastrointestinal tract and other organs.
The pathogenesis of JDM is not fully understood but
environmental factors are thought to trigger the disease
in genetically predisposed children [1–4].
JDM is most commonly diagnosed and classified using
the Bohan and Peter criteria published in 1975 [5, 6].
The criteria include presence of characteristic rashes with
any of symmetrical proximal muscle weakness, elevated
serum muscle enzymes, electromyographic changes and
features of inflammatory myositis on muscle biopsy. The
presence of the skin manifestations together with two of
the other features is required for classification of a patient
as having probable JDM. The characteristic skin lesions
may also occur without apparent muscle involvement and
is referred to as amyopathic dermatomyositis [7].
Data from multicenter patient registries indicate that
the average age of onset of JDM is seven years with greater
incidence in girls than boys (ratio of 2:1) [8–11]. However,
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regional differences exist and studies from India and Saudi
Arabia have reported higher incidence rates in male chil-
dren [12, 13]. JDM occurs in all regions of the world
though some studies suggest that there could be differ-
ences in incidence rates among different racial groups.
Mendez et al. reported a lower incidence rate among chil-
dren of Hispanic ancestry compared to those of African
and Caucasian ancestry in the USA [14]. Racial differences
have also been noted in the incidence rates of certain
disease manifestations with much higher incidence of
calcinosis being reported among children of African an-
cestry compared to other racial groups [9, 15, 16].
The treatment outcome of JDM has improved over the
years with the mortality rate falling significantly from
more than 30 % before routine use of steroids [17], to
less than 5 % in most recent studies [11, 18–20]. Despite
the improvement in mortality rates among JDM pa-
tients, disease and treatment related damage remains a
major challenge and significantly affect the quality of life
of affected individuals. However, data on the characteris-
tics and treatment outcome of JDM patients from Africa
is scarce and only one study has been published that
specifically described a series of JDM patients from the
continent [9]. In that study, a higher rate of calcinosis
and vasculitis compared to that from other regions was
reported suggesting that the clinical manifestations and
outcome of JDM in African patients could be different.
We therefore carried out a study to review and de-
scribe the clinical features and treatment outcomes of
patients seen with JDM from Cape Town, South Africa.
Methods
Study design, study setting and patients
We carried out a retrospective folder review of JDM pa-
tients seen between January 2004 and December 2013 in
three tertiary care hospitals (Tygerberg, Groote Schuur
and Red Cross War Memorial Children’s Hospital) in
Cape Town, South Africa. These three hospitals are the
main tertiary referral hospitals for the Western Cape
Province and also serve the surrounding regions of the
Eastern and Northern Cape provinces of South Africa.
Patients from this catchment area diagnosed with JDM
were likely to have been referred to one of these centres
for evaluation and treatment. The approximate popula-
tion in the primary catchment area was 4.6 Million in
2004 and 6.1 million in mid-2014 with children (people
aged <15 years) constituting 35 and 26.5 % of the
population respectively [21]. The province populace is
composed of people of diverse ancestral backgrounds
with the most populous groups being, in descending
order, people of mixed, indigenous African and European
ancestries [21].
Only patients who were seen between January 2004
and December 2013 and satisfied the Bohan and Peter
criteria for classification as probable or definite JDM
were included. Data was extracted from the patient re-
cords as at the last review prior to 31st December 2014
to allow for a minimum follow up period of one year for
each patient. Data was abstracted onto case record forms
(CRF) and later transcribed onto an excel spreadsheet.
Information collected included: demographics, clinical
and laboratory features, radiological investigation results,
treatment given and treatment outcomes.
The primary outcome variable was disease activity at last
review. Patients were classified as having clinically active
disease or inactive disease. A modification of the PRINTO
criteria for inactive disease [22] was used. The PRINTO
criteria include creatine kinase (CK) < 150 U/L, childhood
myositis assessment scale (CMAS) > 48, Manual muscle
testing score (MMT) > 78 and Physician global (VAS) <0.2.
Patients satisfying any three of these criteria are classified
as having clinically inactive disease. We used a modifica-
tion of these criteria due to difficulties with direct compari-
sons since this was a retrospective study and data on some
of the PRINTO criteria items was not available. Therefore
for this study we modified the criteria as follows (modifica-
tion in brackets): CK < 150 U/L (No modification),
CMAS > 48 (No modification), MMT> 78 (or documented
full muscle strength using any muscle strength assessment
scale by the attending physician) and Physician global
(VAS) <0.2 (or documentation of absence of symptoms
and signs of active disease by the clinician).
Patients were classified as having inactive disease if
they satisfied any three of these criteria. Secondary out-
come measure was damage defined as persistent changes
in anatomy, physiology or function present for at least
6 months at the last review (IMACS definitions of
damage and specific damage items) [23, 24]. Damage
was assessed as being present or absent by systems and
patients classified as either exhibiting damage (any) or
none at last follow up.
Data analysis
Data was analysed using R i386 3.1.0 (The R Foundation
for Statistical Computing, Vienna, Austria) software. Me-
dian and interquartile ranges were used for descriptive
statistics for quantitative variables (non-normally distrib-
uted data). Frequencies were computed for qualitative vari-
ables. Non-parametric tests (Wilcoxon rank sum tests)
were used for comparison of medians across groups. For
comparison between categorical variables, cross-tabulation
with formulation of Fisher’s exact (chi square) statistic was
used. The two sided p-values <0.05 were considered to be
statistically significant.
The study was approved by the human research ethics
committees of Cape Town (HREC/REF: 062/2014) and
Stellenbosch universities (S14/04/080).
Okong’o et al. Pediatric Rheumatology  (2016) 14:60 Page 2 of 8
Results
Patient characteristics
Twenty seven cases with a diagnosis of JDM seen between
2004 and 2013 were identified. Two had amyopathic JDM
and were excluded as they did not meet the inclusion
criteria of probable JDM. Of the other twenty five, twelve
satisfied the criteria for classification as definite JDM. Six of
the thirteen patients with probable JDM also had features
of muscle inflammation on magnetic resonance imaging
(MRI). Sixteen of the patients were female (F:M 1.8:1).
Thirteen (52 %) of the cases were of indigenous African,
eleven (44 %) mixed and one (4 %) European ancestry.
The median age at disease onset was 6.75 (range 2.0–9.7)
years and 7.9 (range 3.4–9.75) years at diagnosis. The me-
dian duration from symptom onset to diagnosis was 4
(range 0.5–84) months. One patient with gottrons papules,
calcinosis, elevated muscle enzymes, severe proximal weak-
ness and arthritis was retrospectively diagnosed with JDM
by the paediatric rheumatology team after a period of
84 months having previously been labelled as discoid lupus.
Diagnostic features and characteristics
Muscle weakness and characteristic cutaneous manifesta-
tions were documented in all the 25 patients. Heliotrope
rash occurred in 20 and Gottron’s papules in 19 of the pa-
tients. Muscle enzymes were elevated in all but one patient.
This patient however, had suggestive muscle biopsy changes
and satisfied the criteria for classification as probable JDM.
Creatine kinase (CK) was elevated in 22 of 24 cases. The
two patients with normal CK had elevated AST and ALT
and in addition one had elevated aldolase and the other
had elevated lactose dehydrogenase (LDH). Aldolase was
only determined in five patients and was elevated in three
of them. Figure 1 summarizes results of the diagnostic pro-
cedures and criteria.
Muscle biopsy was performed in twelve (48 %) of the
patients and showed characteristic features including
perifascicular atrophy, fibre degeneration and regener-
ation and perivascular inflammation consistent with
JDM in 11 (91.7 %) of the cases.
Five of the patients had documented EMG results
showing features consistent with myositis. Muscle MRI
for initial diagnostic work-up was done in nine patients
and demonstrated active inflammation in eight of the
patients. All the patients in whom MRI was done were
diagnosed in the latter half of the period under review
(2009–2013).
Clinical characteristics
There was no documented family history of neuromuscular
or autoimmune diseases among the cases. However, history
of preceding infection was reported in 6 cases: upper re-
spiratory tract infection (URTI) in 4 cases and dental or
skin abscesses in 2 cases with a median time to onset of
JDM symptoms of 1 month (range 1 week – 3 months).
One patient had a traumatic event (sexual abuse) one
month prior to onset of JDM symptoms.
Pulmonary involvement was reported in four patients
and two of them died; one with suspected severe interstitial
lung disease and the other with pulmonary hemorrhage
and sepsis. The third patient had clinical as well as high
resolution computerized tomography (HRCT) scan features
of interstitial lung disease (ILD) and restrictive pattern on
pulmonary function tests (PFTs). One other patient had
deranged spirometry results, which normalized with treat-
ment. Antisynthetase antibodies (anti Jo-1) were tested in
two of these four patients and was negative in both of them.
In total, PFT results were available for six patients (done
after mean of 4.4 years from diagnosis) and only two of
the patients had deranged lung function parameters (re-
strictive pattern).
Cardiovascular involvement was observed in one patient
who presented with generalized oedema and heart failure.
Echocardiography showed mildly dilated chambers with
reduced ejection fractions (EF) of <55 %. This patient had
clinical resolution of symptoms as well as improvement
on the EF on echocardiography. Echocardiography how-
ever, was not routinely done to document baseline state or
monitor cardiac function of JDM patients in the three
centres. Neurological manifestations were seen in two
cases; one had convulsions thought to be due to cerebral
vasculitis and the other had localized sensory neuropathy.
Cutaneous and musculoskeletal manifestations were
the most common and are summarized together with
other clinical features in Table 1. Of note, three patients
had calcinosis at diagnosis and eight others developed
calcinosis during follow up. Calcinosis resolved in three
patients during follow. Figure 2 shows a radiograph of
one of the patients showing tumoural and planar calci-
nosis in the forearm. There was no statistically signifi-
cant difference in the age at onset, age at diagnosis and
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Fig. 1 Diagnostic investigation results. Present: features supportive
of myositis; Absent: not supportive of myositis; Not available: Not
done or results not accessible. Muscle enzymes were elevated in 24
of the 25 patients
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duration of follow up among patients who developed
calcinosis and those who did not have calcinosis. The
median time to diagnosis from symptom onset was
longer in children who had calcinosis (6 months) than
in those who did not have calcinosis (3 months). The dif-
ference was however not statistically significant (p = 0.13).
In addition, even though there was a tendency towards a
higher prevalence of calcinosis among indigenous African
children (8/13) compared to children of other racial back-
grounds (3/12), the difference was not statistically signifi-
cant (p = 0.11).
Laboratory investigations
Among the MSAs, only anti-Jo1 was tested and was nega-
tive in all the six patients tested. ANA results were available
in 19 patients and was low positive in seven (three had
Hep-2 titres of 40, 40 and 100; and four had composite
ANA ratio of 8, 2.2 4.6 and 32 U/L). The results of the
laboratory investigations are summarized in Table 2.
Treatment
Information on treatment was available for 23 of the 25 pa-
tients. We could not locate treatment records in two cases.
The most common drugs used were oral prednisone
(100 %), methotrexate (74 %), intravenous methylpredniso-
lone (39 %) and intravenous immunoglobulin (IVIG, 39 %).
Table 1 Disease manifestations among the JDM cases in Cape
Town
Cumulative clinical
manifestations (%)
Clinical manifestations
at last review
Skin
Calcinosis 11 (44) 8 (32)
Skin ulcers 11 (44) 1
Oedema (Generalized,
Periorbital or limb)
11 (44) 0
Alopecia 3 (12) 3 (12)
Lipodystrophy 1 (4) 1 (4)
Musculoskeletal 7 (28)
Muscle tenderness 13 (52) 0
Arthritis 7 (28) 2 (8)
Contractures 5 (20) 5 (20)
Osteoporosis with
fracture
1 (4) 1 (4)
Endocrine 9 (36) 9 (36)
Growth failure 8 (32) 8 (32)
Diabetes mellitus 1 (4) 1 (4)
Adrenal insufficiency 1 (4) 0
Respiratory 3 (12) 3 (12)
Interstitial lung disease
(ILD)
2 (8) 2 (8)
Dysphonia 2 (8) 0
Pulmonary hemorrhage 1 (4) 1 (4)
Gastrointestinal
Dysphagia 5 (20) 0
Abdominal pain or
bleeding
3 (12) 0
Ocular 2 (8) 2 (8)
Cataracts 2 (8) 2 (8)
Cardiovascular
Abnormal capillaroscopy 15 (60) NA
Raynaud’s phenomenon 6 (24) NA
Cardiomyopathy 1 (4) 0
Nervous system 3 (12) 1 (4)
Seizures; neuropathy 2 (8) 0
Sensorineural hearing loss 1 (4) 1 (4)
Infections
Fungal (skin) 7 (28) NA
Bacterial (staph aureus 2,
gram negative 1)
3 (12) NA
TB 2 (8) NA
Fig. 2 Forearm radiograph showing mixed tumoural and planar
calcinosis in one of the JDM patients
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Prednisone alone was used in five patients, prednisone and
methotrexate without another agent in nine patients and
various other drugs were added as second line drugs to the
main treatment modality (prednisone and methotrexate) in
poor responders as summarized in Fig. 3 below. All the
patients received corticosteroids during the course of their
treatment. Biologics were used in 6 patients (rituximab in
5 and infliximab in 1). Oral steroids were given at a dose
of 2 mg/kg, though there was no uniformity on when
to start to taper the dose and over what duration of
time. The patient who received infliximab had defaulted
from follow up after one dose and was yet to return for
evaluation and further doses by the time of completing
data collection and analysis.
Treatment outcome: diseases activity, mortality and
damage
Of the 25 patients, 10 were still in care, 8 had been dis-
charged, 2 transferred to other centres, 3 were lost to
follow up and 2 died. Ten (40 %) of the patients had
clinically inactive disease. There was no statistically sig-
nificant difference in the median duration of follow up
(p = 0.28), age of onset, race, diagnostic delay and disease
category (probable or definite) between those who had
clinically inactive and active disease. These findings are
summarized in Table 3 below.
The mortality rate was 2/25 (8 %) over a median
follow-up period of 50 months. Death resulted from re-
spiratory failure in the setting of global weakness (and
possible interstitial lung disease) in one patient and from
sepsis, GI bleed and pulmonary hemorrhage (evident at
autopsy) in the other.
Overall, 18 (72 %) of the patients had some docu-
mented damage though a full damage assessment was
hampered by missing data occasioned by the retrospect-
ive nature of the study. The most common systems in
which disease damage was reported were: endocrine (9
cases), skin (8 cases), musculoskeletal (7 cases) and re-
spiratory (3 cases) systems. Endocrine damage was
mainly as a result of growth failure in 9 (40 %) of the pa-
tients though one patient developed treatment (steroid)
associated diabetes mellitus and another, adrenal insuffi-
ciency. Growth failure was defined by the IMACS cri-
teria as presence of two of the following three features:
a. Less than 3 percentile height for age, growth velocity
over 6 months less than 3 percentile for age and growth
curve crossing at least 2 centiles (5 %, 10 %, 25 %, 50 %,
75 %, 95 %) on growth chart.
Table 2 Laboratory investigation results
Investigation Reference
range
Median
(IQR)
No. positive/
No. tested
Percentage
Enzymes
CK 26–145 U/L 1074.0
(222.8–3397.5)
22/24 91.7
Aldolase 3.0–12.0U/L 12.6
(7.7–15.9)
3/5 60
LDH 142–261U/L 445.0
(277.0–493.5)
14/19 73.7
AST 0–41 U/L 74.0
(35.25–140.5)
16/22 72.7
ALT 5–25 U/L 48.0
(26.5–82.0)
18/23 78.3
Autoantibody
Anti-Jo1 <7 EliA U/ml 0.3
(0.3–0.45)
0/6 0
Anti-RNP <7 EliA U/ml 0.3
(0.3–0.5)
0/9 0
Inflammatory markers
ESR 20
(12–35)
11/19 57.9
CRP 2.6
(<1–6)
2/10 20
vWF activity 77
(62–112 %)
2/4 50
0
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Fig. 3 Drugs used in management of Cape Town JDM patients.
Abbreviations: Cyclophos: cyclophosphamide; Medrol: intravenous
methylprednisolone; Pred: Prednisone PredMTX: Prednisone and
methotrexate; IVIG: Intravenous immunoglobulin
Table 3 Determinants of disease activity
Clinically inactive
disease
Clinically active
disease
p-value
Number 10 15
Sex (F/M) 8/2 8/7 p = 0.228a
Race (Indigenous
African/other)
5/5 8/7 P = 1
Age at onset
(Median) years
7.8 6.0 p = 0.868a
Time to diagnosis
(Median) months
3.5 4.5 p = 0.745a
Duration follow up
(Median) months
55.5 49.1 p = 0.28a
Calcinosis (Yes/No) 4/6 6/9 p = 1b
aWilcoxon rank sum test, bFisher exact
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Musculoskeletal damage included one patient who had
osteoporosis with vertebral fracture that was demon-
strated using bone scans (scintigraphy). One patient, who
had suffered from suppurative otitis media during follow
up, developed sensorineural hearing loss. Three patients
had calcinosis at diagnosis, 8 developed calcinosis and
three had resolution of the calcinosis during follow up.
Discussion
A better understanding of the epidemiology and clinical
outcomes of JDM has been enhanced by the establish-
ment of multicenter and multinational collaborations
such as the paediatric rheumatology international trials
organization (PRINTO) and international myositis as-
sessment and clinical studies group (IMACS). However,
data from Africa has been scarce and the epidemiology
of JDM from the continent has been based on extrapola-
tion of data collected from other populations and re-
gions. This study adds to the available data on the
epidemiology and treatment outcome of JDM in Africa.
The median age of onset (6.75 years) and gender com-
position (female: male 1.8:1) among the JDM patients in
our study was similar to that reported by most studies
from other regions with a mean age at disease onset of
seven years and a female predominance of about 2:1 [10,
11, 20]. In the current study, we found a relatively high
rate (44 %) of calcinosis. Children of indigenous African
ancestry appeared to have a higher prevalence of calci-
nosis (61.5 %) compared to patients of other ancestral
background (25 %), though the difference was not statis-
tically significant (p = 0.11). Higher rates of dystrophic
calcinosis have been reported among indigenous African
compared to JDM patients of other ancestral back-
grounds [16]. It is not clear why indigenous African pa-
tients appear to have higher risk of calcinosis.
Certain immune phenotypes associated with presence
of anti-MJ autoantibodies, found in 12–23 % of JIIM pa-
tients, have been associated with higher risk of occur-
rence of calcinosis and severer disease [25]. It is not
known if black African children have higher prevalence
of these immune phenotypes thus putting them at
greater risk for calcinosis. The immune phenotype was
not determined for our patients and published studies
are not available on the comparative prevalence of auto-
antibody and other associated risk factor profiles among
indigenous African compared to children of other ances-
tral backgrounds.
Increased risk of calcinosis and other disease damage
could also be related to poor access to care with subse-
quent inappropriate and delay in instituting treatment.
Delay in diagnosis may be the consequence of lack of
access to clinicians skilled in diagnosing and managing
dermatomyositis and similar conditions; and lack of
access to diagnostic facilities such as EMG and muscle
biopsy. However, there was no significant difference in
the delay in making a diagnosis between the patients of
indigenous African and patients of other ancestral ori-
gins (p = 0.27).
As the search for better and more acceptable diagnos-
tic procedures and tools continues, MRI is gradually be-
ing used in the three centres instead of or in addition to
EMG and muscle biopsy for diagnosis of JDM. Nine
muscle MRIs were done as part of the diagnostic evalu-
ation of children; all in the latter half of the period under
review. Thus MRI seems to have gained prominence as a
diagnostic tool for JDM consistent with findings from
other studies [19, 26, 27]. However, in Africa and many
other resource constrained economies, MRI may not be
available in many centres and even where it is available,
long waiting times, technical issues with reporting and
cost implications may prove prohibitive. Thus additional
diagnostic modalities such as muscle ultrasound and
Bone scintigraphy that may provide cheaper and more
convenient alternatives for demonstrating evidence of
muscle inflammation may be welcome [28–30].
The mortality rate (8 %, 1 death per 52 patient years) in
our series appears higher than the 2–4 % reported in most
recent studies from other regions [11, 18–20]. This finding
was consistent with that by Faller et al. [9] who reported a
mortality of 9.5 % (1 death per 27.3 patient years) among
indigenous African children with JDM from Johannes-
burg, South Africa. These two studies were small and it’s
not possible to draw generalizable conclusions. They how-
ever provide some insight into possible treatment out-
comes of JDM in Africa. Two deaths were reported in our
study as well as in the study by Faller et al. and all the four
deaths resulted from respiratory (involvement) disease
which has been identified as an early disease feature pre-
dictive of mortality [18].
Juvenile dermatomyositis is a chronic disease and
many patients may never achieve a clinically inactive dis-
ease state. After a median follow up time of 50 months,
only ten (40 %) of the 25 patients had clinically inactive
disease (modified PRINTO criteria) at their last follow
up. Sanner et al. studied the long-term outcome of JDM
and after 16.8 years, 59 % of the patients still had clinic-
ally active disease [31]. Similarly, Sun eta al analyzed the
treatment outcome among JDM patients over a ten year
period in a Taiwanese hospital found that only 33 %
among the cohort of 39 patients were symptom free at
last review [32]. It is thus clear that most children with
JDM have long-term inflammation and disease activity
that linger long after initiation of treatment. Formulation
of appropriate guidelines and standard of care protocols
to guide short-term and long-term management of JDM
in resource poor settings could enable appropriate
timely interventions for better treatment outcomes.
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Conclusion
The demographic characteristics of JDM patients from
Cape Town (median disease onset age of 6.75 years and
Female to male ration of 1.8:1) was similar to that re-
ported from most regions of the world. It is probable that
there was unnecessary delay in the diagnosis of some of
the cases and in one instance, diagnosis was made retro-
spectively seven years after disease onset. Further, there
was persistent clinically active disease in a large propor-
tion of this cohort (60 %), putting them at risk of further
disease complications. This could be a reflection of inad-
equate or less aggressive treatment. In concurrence with
findings by other authors, this study found a relatively
high rate of calcinosis among African patients with JDM.
A prospective study to determine the factors associated
with this heightened risk of calcinosis could be useful. The
study adds to the available literature on JDM in Africa and
demonstrates a need for a defined standard of care pack-
age to ensure adequate access to skilled multidisciplinary
teams, essential diagnostic facilities and therapeutic re-
sources for better treatment outcomes.
The study limitations included missing values and the
relatively small number of cases identified. Further, we
used an unvalidated modification of the PRINTO criteria
for determination of disease activity which may raise
questions on comparability of our results to findings
from other studies. Establishment of a prospective co-
hort in future could be useful in providing better quality
data for better outcome assessments in line with cur-
rently accepted international guidelines.
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